Survodutide for the Treatment of Obesity
JACC: Heart Failure · 2024-12 · 12 (12) · 2101-2109
DOI: 10.1016/j.jchf.2024.09.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Heart Failure, 2024-12. Verfasst von Mikhail N Kosiborod und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, M…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Obesity. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim International GmbH.
Abstract (Originalsprache)
Dual agonism of glucagon and glucagon-like peptide-1 (GLP-1) receptors may be more effective than GLP-1 receptor agonism alone in reducing body weight, but the cardiovascular (CV) effects are unknown. The authors describe the rationale and design of SYNCHRONIZE-CVOT, a phase 3, randomized, double-blind, parallel-group, event-driven, CV safety study of survodutide, a dual glucagon and GLP-1 receptor agonist, administered subcutaneously once weekly compared with placebo in adults with a body mass index ≥27 kg/m2 and established CV disease or chronic kidney disease, and/or at least 2 weight-related complications or risk factors for CV disease. The primary endpoint of SYNCHRONIZE-CVOT is time to first occurrence of the composite adjudicated endpoint of 5-point major adverse CV events. This global CV outcomes trial is currently enrolling, with a target recruitment of 4,935 participants. SYNCHRONIZE-CVOT is the first trial that will determine the CV safety and efficacy of survodutide in people with obesity and increased CV risk. (A Study to Test the Effect of Survodutide [BI 456906] on Cardiovascular Safety in People With Overweight or Obesity [SYNCHRONIZE-CVOT]; NCT06077864).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. Electronic address: mkosiborod@saint-lukes.org.
- Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- St. Vincent's University Hospital and University College Dublin School of Medicine, Dublin, Ireland.
- Boehringer Ingelheim International GmbH, Ingelheim, Germany; 1st Department of Medicine, University Medical Center Mannheim, Heidelberg University, Mannheim, Germany.
- Boehringer Ingelheim International GmbH, Ingelheim, Germany.
Förderung
- Boehringer Ingelheim International GmbH
Zitieren
APA
Kosiborod, M. N., Platz, E., Wharton, S., le Roux, C. W., Brueckmann, M., Ajaz Hussain, S., Unseld, A., Startseva, E., Kaplan, L. M., & SYNCHRONIZE–CVOT Trial Committees and Investigators (2024). Survodutide for the Treatment of Obesity. JACC: Heart Failure, 12(12), 2101-2109. https://doi.org/10.1016/j.jchf.2024.09.004
Vancouver
Kosiborod MN, Platz E, Wharton S, le Roux CW, Brueckmann M, Ajaz Hussain S, et al. Survodutide for the Treatment of Obesity. JACC: Heart Failure. 2024;12(12):2101-2109. doi:10.1016/j.jchf.2024.09.004
BibTeX
@article{Kosiborod2024,
author = {Kosiborod, Mikhail N and Platz, Elke and Wharton, Sean and le Roux, Carel W and Brueckmann, Martina and Ajaz Hussain, Samina and Unseld, Anna and Startseva, Elena and Kaplan, Lee M and SYNCHRONIZE–CVOT Trial Committees and Investigators, SYNCHRONIZE–CVOT Trial Committees and Investigators},
title = {Survodutide for the Treatment of Obesity},
journal = {JACC: Heart Failure},
year = {2024},
volume = {12},
number = {12},
pages = {2101--2109},
doi = {10.1016/j.jchf.2024.09.004}
}
EUVIMED